Marvel Biosciences announced a non-brokered private placement offering of 10 to 20 million units at $0.15 each, aiming to raise $1.5 to $3 million. Each unit includes one common share and a warrant to buy another share at $0.20, exercisable after 61 days for one year. The funds will support phase 1 clinical trials for their lead compound MB-204, cover administrative costs, and provide working capital. The offering is subject to regulatory approval and expected to close around August 14, 2026.
UK GDP grew 0.8% over three months, surpassing forecasts and showing resilience despite geopolitical tensions and energy price pressures. The FTSE 100 opened lower as investors digested takeover deals including Rotork's £4.1bn acquisition by ABB and ...
The FTSE 100 index fell slightly, dragged down by mining stocks reacting to China's slower GDP growth of 4.3% in Q2, its weakest in three years. Despite this, oil prices remained steady amid US-Iran tensions. PayPal shares jumped over 14% following r...
The Goldman Sachs Future Tech Leaders Equity ETF (GTEK) has delivered a 48.9% return year-to-date, nearly doubling the 25% return of the Vanguard Information Technology ETF (VGT). Unlike VGT, which heavily invests in mega-cap tech giants like Nvidia,...
